Human <i>RPE65</i> Gene Therapy for Leber Congenital Amaurosis: Persistence of Early Visual Improvements and Safety at 1 Year
Artur V. Cideciyan(University of Pennsylvania), Samuel G. Jacobson(Penn Presbyterian Medical Center), Tomás S. Alemán(Children's Hospital of Philadelphia), Thomas J. Conlon(Adelson Foundation), Alejandro J. Román(Penn Presbyterian Medical Center), Elizabeth A. M. Windsor(Penn Presbyterian Medical Center), Alexander Sumaroka(Penn Presbyterian Medical Center), Barry J. Byrne(University of Florida), William W. Hauswirth(University of Florida), Sharon Schwartz(Penn Presbyterian Medical Center), Jijing Pang(He University), Shalesh Kaushal(University of Florida), Sanford L. Boye(University of Florida)
Cited by 312
Related Papers
Treatment of Leber Congenital Amaurosis Due to <i>RPE65</i> Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial
|Human Gene Therapy|2008|950
Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fate
|Nature Genetics|2000|506
Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo
|Circulation Research|2006|400
Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism
|Journal of Virology|2000|392
Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy
|Proceedings of the National Academy of Sciences|2009|322